Caitlin C Murphy1, Bianca M Sigel2, Edward Yang3, Celette Sugg Skinner1, Ethan A Halm4, Samir Gupta5, Joanne M Sanders2, Katharine McCallister2, Amit G Singal4. 1. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 2. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 3. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 4. Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 5. Department of Internal Medicine, University of California San Diego, La Jolla, California, USA; Veterans Affairs San Diego Health Care System, San Diego, California, USA.
Abstract
BACKGROUND AND AIMS: Colorectal cancer (CRC) screening can reduce CRC incidence and mortality, but measuring screening adherence over time is challenging. We examined adherence using a novel measure characterizing the proportion of time covered (PTC) by screening tests. METHODS: Eligible patients were age 50 to 60 years and followed at a large, safety-net health care system between January 2010 and September 2014. We estimated PTC as the number of days up to date with screening divided by the number of days from cohort entry until study end, CRC diagnosis, or death. We estimated mean and median PTC and used least-significant difference tests to assess differences in adherence by patient characteristics. RESULTS: Of 18,257 patients, most were non-Hispanic black (40.5%) or Hispanic (34.9%) and/or female (62.4%). Approximately 40% (n = 7559) were never screened during the study period; the remaining 10,698 patients completed 19,105 screening examinations (14,481 fecal immunochemical tests [FITs], 4393 colonoscopies, 94 sigmoidoscopies, and 137 barium enemas). Overall, the mean PTC was 29.1% (95% confidence interval [CI], 28.6%-29.5%). Among those who completed at least one screening test (n = 10,698), the mean PTC was 49.0% (95% CI, 48.5%-49.5%). The most common reasons for non-adherence were lack of repeat FIT and no diagnostic colonoscopy after abnormal results for the FIT. The mean PTC increased with the number of primary care visits (0 visits, 21%; 1 visit, 29%; 2-3 visits, 35%; ≥4 visits, 37%; all P < .05). CONCLUSIONS: PTC provides a reliable estimate of screening adherence, capturing breakdowns in the CRC screening process amenable to intervention. Repeat FIT and diagnostic colonoscopy are important intervention targets that may increase adherence in underserved populations.
BACKGROUND AND AIMS: Colorectal cancer (CRC) screening can reduce CRC incidence and mortality, but measuring screening adherence over time is challenging. We examined adherence using a novel measure characterizing the proportion of time covered (PTC) by screening tests. METHODS: Eligible patients were age 50 to 60 years and followed at a large, safety-net health care system between January 2010 and September 2014. We estimated PTC as the number of days up to date with screening divided by the number of days from cohort entry until study end, CRC diagnosis, or death. We estimated mean and median PTC and used least-significant difference tests to assess differences in adherence by patient characteristics. RESULTS: Of 18,257 patients, most were non-Hispanic black (40.5%) or Hispanic (34.9%) and/or female (62.4%). Approximately 40% (n = 7559) were never screened during the study period; the remaining 10,698 patients completed 19,105 screening examinations (14,481 fecal immunochemical tests [FITs], 4393 colonoscopies, 94 sigmoidoscopies, and 137 barium enemas). Overall, the mean PTC was 29.1% (95% confidence interval [CI], 28.6%-29.5%). Among those who completed at least one screening test (n = 10,698), the mean PTC was 49.0% (95% CI, 48.5%-49.5%). The most common reasons for non-adherence were lack of repeat FIT and no diagnostic colonoscopy after abnormal results for the FIT. The mean PTC increased with the number of primary care visits (0 visits, 21%; 1 visit, 29%; 2-3 visits, 35%; ≥4 visits, 37%; all P < .05). CONCLUSIONS: PTC provides a reliable estimate of screening adherence, capturing breakdowns in the CRC screening process amenable to intervention. Repeat FIT and diagnostic colonoscopy are important intervention targets that may increase adherence in underserved populations.
Authors: Laura C Seeff; Thomas B Richards; Jean A Shapiro; Marion R Nadel; Diane L Manninen; Leslie S Given; Fred B Dong; Linda D Winges; Matthew T McKenna Journal: Gastroenterology Date: 2004-12 Impact factor: 22.682
Authors: Ethan A Halm; Elisabeth F Beaber; Dale McLerran; Jessica Chubak; Douglas A Corley; Carolyn M Rutter; Chyke A Doubeni; Jennifer S Haas; Bijal A Balasubramanian Journal: J Gen Intern Med Date: 2016-06-08 Impact factor: 5.128
Authors: Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham Journal: Lancet Date: 1996-11-30 Impact factor: 79.321
Authors: Elisabeth F Beaber; Jane J Kim; Marilyn M Schapira; Anna N A Tosteson; Ann G Zauber; Ann M Geiger; Aruna Kamineni; Donald L Weaver; Jasmin A Tiro Journal: J Natl Cancer Inst Date: 2015-05-07 Impact factor: 13.506
Authors: Jasmin A Tiro; Aruna Kamineni; Theodore R Levin; Yingye Zheng; Joanne S Schottinger; Carolyn M Rutter; Douglas A Corley; Celette S Skinner; Jessica Chubak; Chyke A Doubeni; Ethan A Halm; Samir Gupta; Karen J Wernli; Carrie Klabunde Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-10 Impact factor: 4.254
Authors: Susan A Sabatino; Mary C White; Trevor D Thompson; Carrie N Klabunde Journal: MMWR Morb Mortal Wkly Rep Date: 2015-05-08 Impact factor: 17.586
Authors: Caitlin C Murphy; Ethan A Halm; Celette Sugg Skinner; Bijal A Balasubramanian; Amit G Singal Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-26 Impact factor: 4.254
Authors: Debra T Choi; Hye-Chung Kum; Sulki Park; Robert L Ohsfeldt; Yu Shen; Neehar D Parikh; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2018-10-26 Impact factor: 11.382
Authors: Adil Faqih; Amit G Singal; Hannah M Fullington; Benjamin Hewitt; Ezra Burstein; Purva Gopal; Annika Wylie; John Abrams; Caitlin C Murphy Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254
Authors: Jessica Chubak; Melissa L Anderson; Andrea J Cook; Caitlin C Murphy; Michael L Jackson; Beverly B Green Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-05-28 Impact factor: 4.254
Authors: Neehar D Parikh; Nabihah Tayob; Taim Al-Jarrah; Jennifer Kramer; Jennifer Melcher; Donna Smith; Patrick Marquardt; Po-Hong Liu; Runlong Tang; Fasiha Kanwal; Amit G Singal Journal: JAMA Netw Open Date: 2022-07-01
Authors: Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon Journal: J Gen Intern Med Date: 2021-05-28 Impact factor: 6.473